GH logo

Guardant Health Inc. (GH)

$143.28

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GH

Market cap

$19.38B

EPS

-3.69

P/E ratio

--

Price to sales

19

Dividend yield

--

Beta

1.679211

Price on GH

Previous close

$144.03

Today's open

$148.57

Day's range

$141.04 - $149

52 week range

$74.55 - $191.05

Profile about GH

CEO

Helmy Eltoukhy

Employees

2506

Headquarters

Palo Alto, CA

Exchange

Nasdaq Global Select

Shares outstanding

135285975

Issue type

Common Stock

GH industries and sectors

Healthcare

Medical Diagnostics & Screening

News on GH

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 13, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 86,192 shares of its common stock to 118 new non-executive employees with a grant date of November 9, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The.

news source

Business Wire • Nov 13, 2026

news preview

Guardant Health Prices $500 Million Convertible Senior Notes Offering

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the n.

news source

Business Wire • Nov 12, 2026

news preview

Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient's cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients that may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer and i.

news source

Business Wire • Nov 11, 2026

news preview

Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Guardant Health also intends to grant t.

news source

Business Wire • Nov 11, 2026

news preview

PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorectal cancer metastases. The study paired pretreatment comprehensive genomic profiling (CGP) using Gu.

news source

Business Wire • Nov 10, 2026

news preview

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 1 at 8:00 a.m. Eastern Time Interested parties may access live and archived.

news source

Business Wire • Nov 9, 2026

news preview

What Guardant Health (GH) Said on Its Q3 Earnings Call

Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based cancer screening test.

news source

MarketBeat • Nov 6, 2026

news preview

Guardant Health, Inc. (GH) Q3 2026 Earnings Call Transcript

Guardant Health, Inc. (GH) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights For the three-month period ended September 30, 2026, as compared to the same period of 2025: Reported total revenue of $361.0 million, an increase of 36%, driven by: Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58% Bioph.

news source

Business Wire • Nov 5, 2026

news preview

Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Guardant Health Inc.

Open an M1 investment account to buy and sell Guardant Health Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GH on M1